OliX Pharmaceuticals, Inc.

Industry

  • Biotechnology
    • Antisense, Oligonucleotides
    • Drug Discovery Technologies
      • Genomics-Proteomics
      • ADMET
  • Pharmaceuticals

Other Names/Subsidiaries

  • Biomolecular Therapeutics
  • mCureX Therapeutics
See more in Biomedtracker

Latest on OliX Pharmaceuticals, Inc.

Scrip

Asia Deal Watch: AstraZeneca Buys FibroGen’s Chinese Subsidiary

 
• By Joseph Haas, Vibha Ravi, Lisa Takagi, Dexter Jie Yan, and Jung Won Shin

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Asia Deal Watch is supported by deal intelligence from Biomedtracker. Deal Brings AstraZeneca Greater C

Scrip

Q2 Korean Biotech Roundup: Partners Return Multiple Assets

 
• By Jung Won Shin

Disappointing news appeared to overflow in the South Korean biotech sector in the second quarter amid multiple returned assets from global partners, a lack of major new out-licensing deals, as well as

Scrip

FibroGen Rocked By Second Pivotal Pamrevlumab Failure – This Time In IPF

 
• By Ayisha Sharma

FibroGen, Inc. ’s monoclonal antibody candidate pamrevlumab has disappointed in the Phase III ZEPHYRUS-1 trial in idiopathic pulmonary fibrosis (IPF), rendering the drug’s future prospects even more u

Scrip

Asia Deal Watch: invoX Builds Novel Pipeline Through $161m F-star Acquisition

 
• By Joseph Haas, Lisa Takagi, Ian Haydock, and Mandy Jackson

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Sino Biopharm Subsidiary Grows Innovati